Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IN8bio ( (INAB) ) has shared an announcement.
On October 27, 2025, IN8bio presented new preclinical data for its γδ T cell engager program, INB-619, at the American College of Rheumatology Convergence Meeting in Chicago. The data demonstrated that INB-619 achieved complete B cell depletion with efficacy comparable to FDA-approved compounds, while minimizing adverse cytokine release. This highlights the potential of INB-619 to transform autoimmune disease treatment by safely and precisely eliminating pathogenic B cells and driving immune reset, showcasing IN8bio’s capabilities in γδ T cell biology.
The most recent analyst rating on (INAB) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on IN8bio stock, see the INAB Stock Forecast page.
Spark’s Take on INAB Stock
According to Spark, TipRanks’ AI Analyst, INAB is a Underperform.
IN8bio’s stock score reflects significant financial challenges, typical of early-stage biotechnology companies. The financial performance is hindered by substantial operational losses and reliance on external funding, while technical analysis shows bearish market trends. Valuation remains speculative with a negative P/E ratio, emphasizing the high-risk nature of investing in developmental biotech firms.
To see Spark’s full report on INAB stock, click here.
More about IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases. The company is advancing several programs, including INB-100 for acute myeloid leukemia and INB-600 for oncology and autoimmune indications.
Average Trading Volume: 70,935
Technical Sentiment Signal: Sell
Current Market Cap: $9.71M
See more data about INAB stock on TipRanks’ Stock Analysis page.